NOS2 and breast carcinoma: In various cancers – including colorectal cancer, gastric cancer, hepatocellular carcinoma, melanoma, breast cancer, leukemia, prostate cancer, esophageal cancer, and cervical cancer – elevated expression of iNOS is significantly associated with poor patient survival outcomes [188,189].